Research programme: antibody therapeutics - Arch Biopartners
Latest Information Update: 23 Jun 2021
At a glance
- Originator Arch Biopartners
- Class Anti-inflammatories; Monoclonal antibodies; Single-domain antibodies
- Mechanism of Action Dipeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Inflammation